GlaxoSmithKline, Pozen say Trexima offers consistent migraine relief

By Elaine Rigoli

Tampa, Fla., Sept. 20 - GlaxoSmithKline plc and Pozen, Inc. said new data examining more than 4,200 migraine attacks in more than 1,100 patients demonstrated that Trexima delivered consistent efficacy over multiple migraine attacks.

Pozen, a Chapel Hill, N.C.-based pharmaceutical company, said a new analysis of four studies showed that patients who treated their migraines with Trexima while pain was mild and within one hour of the start of pain were nearly twice as likely to be pain-free at two hours and remain pain-free through 24 hours, compared to those who waited until the pain was more severe.

GlaxoSmithKline, a New York pharmaceutical company, said Trexima may address an unmet need among migraine sufferers, who frequently cite inconsistent effectiveness as a reason for their dissatisfaction with their medicine. Additionally, Trexima was generally well tolerated across both studies.

Trexima is the proposed brand name for a tablet containing sumatriptan 85 mg formulated with RT Technology and naproxen sodium 500 mg. The drug is currently under review by the Food and Drug Administration for the acute treatment of migraines in adults.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.